Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alexandria Real Estate Equities Inc (ARE) vs AstraZeneca plc (AZN) Price & Performance

Alexandria Real Estate Equities IncTrade
AstraZeneca plcTrade

Price performance (Past 24H)

Key statistics

Alexandria Real Estate Equities Inc vs AstraZeneca plc — how do they compare? Alexandria Real Estate Equities Inc trades at $48.5 (market cap $8.28B), while AstraZeneca plc trades at $158.2 (market cap $248.14B). The key difference: AstraZeneca plc is far larger — about 30× Alexandria Real Estate Equities Inc's market cap, and Alexandria Real Estate Equities Inc pays the higher dividend (5.99%). Which is the better fit depends on your goals.

AREAZN
Market Cap
$8.28B$248.14B
Sector
Real EstateHealth
52-Week High
$87.45$209.48
52-Week Low
$40.41$147.06
Enterprise Value
$20.98B$275.41B
Dividend Yield
5.99%2.01%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alexandria Real Estate Equities Inc

Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.

Read more on ARE

About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Read more on AZN